Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference newsletter

  Breast Cancer

  Free Subscription


1 AJR Am J Roentgenol
3 Ann Surg Oncol
5 Anticancer Res
3 BMC Cancer
1 Br J Cancer
1 Breast Cancer
9 Breast Cancer Res Treat
3 Breast J
1 Cancer Epidemiol Biomarkers Prev
3 Cancer Lett
1 Clin Cancer Res
1 Curr Treat Options Oncol
2 Int J Radiat Oncol Biol Phys
1 J Biol Chem
1 J Clin Invest
1 J Natl Cancer Inst
1 J Nucl Med
2 Lancet Oncol
2 NPJ Breast Cancer
1 Oncogene
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. NIELL BL, Abdalah M, Stringfield O, Raghunand N, et al
    Quantitative measures of background parenchymal enhancement predict breast cancer risk.
    AJR Am J Roentgenol. 2020 Sep 2. doi: 10.2214/AJR.20.23804.
    PubMed         Abstract available

    Ann Surg Oncol

  2. KANTOR O, Wakeman M, Weiss A, Wong S, et al
    Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.
    Ann Surg Oncol. 2020 Aug 31. pii: 10.1245/s10434-020-09073.
    PubMed         Abstract available

  3. COOK JA, Hassanein AH
    ASO Author Reflections: Immediate Lymphatic Reconstruction: A Proactive Approach to Breast Cancer-Related Lymphedema.
    Ann Surg Oncol. 2020 Sep 4. pii: 10.1245/s10434-020-09110.

  4. CHEN JJ, von Eyben R, Gutkin PM, Hawley E, et al
    Development of a Classification Tree to Predict Implant-Based Reconstruction Failure with or without Postmastectomy Radiation Therapy for Breast Cancer.
    Ann Surg Oncol. 2020 Sep 1. pii: 10.1245/s10434-020-09068.
    PubMed         Abstract available

    Anticancer Res

  5. STRAVODIMOU A, Voutsadakis IA
    The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
    Anticancer Res. 2020;40:4829-4841.
    PubMed         Abstract available

  6. SUGISAWA N, Hamada K, Han Q, Yamamoto J, et al
    Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
    Anticancer Res. 2020;40:4869-4874.
    PubMed         Abstract available

  7. BHATTARAI PY, Oh CH, Kim G, Kim MS, et al
    Novel Imidazo[2,1-b]oxazole Derivatives Inhibit Epithelial Cell Transformation and Triple Negative Breast Cancer Tumorigenesis.
    Anticancer Res. 2020;40:5081-5090.
    PubMed         Abstract available

  8. LEE HS, Oh DS
    Assessing the Anti-cancer Therapeutic Mechanism of a Herbal Combination for Breast Cancer on System-level by a Network Pharmacological Approach.
    Anticancer Res. 2020;40:5097-5106.
    PubMed         Abstract available

  9. MINAMI H, Ando Y, Tamura K, Tajima T, et al
    Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:5229-5235.
    PubMed         Abstract available

    BMC Cancer

  10. SHIRMOHAMMADI E, Ebrahimi SS, Farshchi A, Salimi M, et al
    The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages.
    BMC Cancer. 2020;20:836.
    PubMed         Abstract available

  11. JIANG H, Li X, Wang W, Dong H, et al
    Long non-coding RNA SNHG3 promotes breast cancer cell proliferation and metastasis by binding to microRNA-154-3p and activating the notch signaling pathway.
    BMC Cancer. 2020;20:838.
    PubMed         Abstract available

  12. SCHWEDHELM TM, Rees JR, Onega T, Zipkin RJ, et al
    Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
    BMC Cancer. 2020;20:847.
    PubMed         Abstract available

    Br J Cancer

  13. ELSHARAWY KA, Mohammed OJ, Aleskandarany MA, Hyder A, et al
    The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer.
    Br J Cancer. 2020 Sep 1. pii: 10.1038/s41416-020-01045.
    PubMed         Abstract available

    Breast Cancer

  14. OGATA R, Kishino E, Saitoh W, Koike Y, et al
    Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Breast Cancer. 2020 Aug 28. pii: 10.1007/s12282-020-01150.
    PubMed         Abstract available

    Breast Cancer Res Treat

  15. ZHANG Y, Liu J, Raj-Kumar PK, Sturtz LA, et al
    Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05884.
    PubMed         Abstract available

  16. SUN Y, Li Y, Wu J, Tian H, et al
    Nomograms for prediction of overall and cancer-specific survival in young breast cancer.
    Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05870.
    PubMed         Abstract available

  17. TRACEY N, Creedon H, Kemp AJ, Culley J, et al
    HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
    Breast Cancer Res Treat. 2020;179:543-555.
    PubMed         Abstract available

  18. KIM JY, Park K, Im SA, Jung KH, et al
    Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
    Breast Cancer Res Treat. 2020 Aug 28. pii: 10.1007/s10549-020-05891.
    PubMed         Abstract available

  19. HOWELL SJ, Coe F, Wang X, Horsley L, et al
    Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).
    Breast Cancer Res Treat. 2020 Aug 29. pii: 10.1007/s10549-020-05868.
    PubMed         Abstract available

  20. LYNGE E, Beau AB, von Euler-Chelpin M, Napolitano G, et al
    Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark.
    Breast Cancer Res Treat. 2020 Aug 30. pii: 10.1007/s10549-020-05896.
    PubMed         Abstract available

  21. NIETZ S, O'Neil DS, Ayeni O, Chen WC, et al
    A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection.
    Breast Cancer Res Treat. 2020 Sep 1. pii: 10.1007/s10549-020-05889.
    PubMed         Abstract available

  22. SCHAIRER C, Hablas A, Eldein IAS, Gaafar R, et al
    Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.
    Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05864.
    PubMed         Abstract available

  23. GONZALEZ-SANTIAGO S, Saura C, Ciruelos E, Alonso JL, et al
    Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
    Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05866.
    PubMed         Abstract available

    Breast J

  24. WHITE RE, Warren L, Nakhlis F, Rosenbluth J, et al
    Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program.
    Breast J. 2020 Sep 1. doi: 10.1111/tbj.14030.
    PubMed         Abstract available

  25. PATWARI A, Bhatlapenumarthi V
    Diffuse peritoneal carcinomatosis with ascites and disseminated bone marrow carcinomatosis as initial presentation of occult breast cancer.
    Breast J. 2020 Aug 31. doi: 10.1111/tbj.14032.

  26. PASRICHA S, Menon V, Gupta G, Kamboj M, et al
    Impact of 2018 ASCO/CAP guidelines on HER-2 reporting categories of IHC and reflex FISH in breast cancer.
    Breast J. 2020 Aug 31. doi: 10.1111/tbj.14031.
    PubMed         Abstract available

    Cancer Epidemiol Biomarkers Prev

  27. PURRINGTON KS, Raychaudhuri S, Simon MS, Clark J, et al
    Heritable susceptibility to breast cancer among African American women in the Detroit Research on Cancer Survivors Study.
    Cancer Epidemiol Biomarkers Prev. 2020 Aug 31. pii: 1055-9965.EPI-20-0564.
    PubMed         Abstract available

    Cancer Lett

  28. RIOS-LUCI C, Diaz-Rodriguez E, Gandullo-Sanchez L, Diaz-Gil L, et al
    Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
    Cancer Lett. 2020;470:161-169.
    PubMed         Abstract available

  29. LIANG S, Chen Z, Jiang G, Zhou Y, et al
    Corrigendum to "Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals"[Cancer Lett. 386 (2017)12-23].
    Cancer Lett. 2020 Aug 25. pii: S0304-3835(20)30392.

  30. MA L, Wang L, Nelson AT, Han C, et al
    27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.
    Cancer Lett. 2020 Aug 27. pii: S0304-3835(20)30435.
    PubMed         Abstract available

    Clin Cancer Res

  31. HUNTER NB, Kilgore MR, Davidson NE
    The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility.
    Clin Cancer Res. 2020 Aug 28. pii: 1078-0432.CCR-20-2451.
    PubMed         Abstract available


  32. FUJIKAWA H, Wakabayashi T
    Pulmonary tumour thrombotic microangiopathy.
    CMAJ. 2020;192:E256.

  33. WARNER E, Glass K, Foong S, Sandwith E, et al
    Update on fertility preservation for younger women with breast cancer.
    CMAJ. 2020;192:E1003-E1009.

    Curr Treat Options Oncol

  34. MILLER E, Schwartzberg L
    Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.
    Curr Treat Options Oncol. 2020;21:89.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  35. JAOUDE JA, Kayali M, de Azambuja E, Makki M, et al
    De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or not to Boost?
    Int J Radiat Oncol Biol Phys. 2020 Aug 27. pii: S0360-3016(20)34197.
    PubMed         Abstract available

  36. NICOLAS E, Khalifa N, Laporte C, Kirova Y, et al
    Safety Margins for the Delineation of the Left Anterior Descending Artery in patients treated for breast cancer.
    Int J Radiat Oncol Biol Phys. 2020 Aug 27. pii: S0360-3016(20)34198.
    PubMed         Abstract available

    J Biol Chem

  37. FARRINGTON CC, Yuan E, Mazhar S, Izadmehr S, et al
    Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
    J Biol Chem. 2020;295:757-770.
    PubMed         Abstract available

    J Clin Invest

  38. DE HEER EC, Jalving M, Harris AL
    HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer.
    J Clin Invest. 2020 Sep 1. pii: 137552. doi: 10.1172/JCI137552.
    PubMed         Abstract available

    J Natl Cancer Inst

  39. Corrigendum: Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    J Natl Cancer Inst. 2020 Sep 3. pii: 5901262. doi: 10.1093.

    J Nucl Med

  40. KUMAR M, Salem K, Jeffery JJ, Yan Y, et al
    Longitudinal molecular imaging of progesterone receptor reveals early differential response to endocrine therapy in breast cancer with an activating ESR1 mutation.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.249508. doi: 10.2967/jnumed.120.249508.
    PubMed         Abstract available

    Lancet Oncol

  41. TELLI ML
    BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?
    Lancet Oncol. 2020 Aug 27. pii: S1470-2045(20)30431.

  42. DIERAS V, Han HS, Kaufman B, Wildiers H, et al
    Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2020 Aug 27. pii: S1470-2045(20)30447.
    PubMed         Abstract available

    NPJ Breast Cancer

  43. XIE Y, Davis Lynn BC, Moir N, Cameron DA, et al
    Breast cancer gene expression datasets do not reflect the disease at the population level.
    NPJ Breast Cancer. 2020;6:39.
    PubMed         Abstract available

  44. GADALETA E, Fourgoux P, Pirro S, Thorn GJ, et al
    Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancer.
    NPJ Breast Cancer. 2020;6:38.
    PubMed         Abstract available


  45. MURRAY AS, Hyland TE, Sala-Hamrick KE, Mackinder JR, et al
    The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy.
    Oncogene. 2020 Aug 31. pii: 10.1038/s41388-020-01436.
    PubMed         Abstract available

    PLoS One

  46. PHILIPOVSKIY A, Dwivedi AK, Gamez R, McCallum R, et al
    Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer.
    PLoS One. 2020;15:e0238262.
    PubMed         Abstract available

  47. FERRANTI M, Pinnarelli L, Rosa A, Pastorino R, et al
    Evaluation of the breast cancer care network within the Lazio Region (Central Italy).
    PLoS One. 2020;15:e0238562.
    PubMed         Abstract available

  48. BISHOP MR, Omeler-Fenaud SM, Huskey ALW, Merner ND, et al
    Gene panel screening for insight towards breast cancer susceptibility in different ethnicities.
    PLoS One. 2020;15:e0238295.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.